# PROVIDER BULLETIN PROVIDER INFORMATION



March 2, 2020

# Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers – eviCore Healthcare Specialty Utilization Management (UM) Program

The eviCore Healthcare Utilization Management Program will be making the following updates to the Medical Oncology CPT® Prior Authorization (PA) Code List.

The following medications are awaiting regulatory approval. When approved, the medications will automatically be added to the PA list for oncologic reasons effective immediately. CPT® codes will be assigned closer to the approval date.

Drug Name	Brand Name (s)
Leuprolide mesylate 50 mg depot	FP-001
Tafasitamab	MOR208
Isatuximab	
Lisocabtagene maraleucel	
Sacituzumab govitecan	
Avapritinib	
Neratinib	Nerlynx
Selumetinib	
Selinexor	Xpovio
Tucatinib	
Niraparib	Zejula

### **Products Impacted**

This change only applies to **fully insured commercial** and **Medicare Advantage** subscribers.

Prior authorization requests will be reviewed based on eviCore clinical guideline criteria. Providers can view the list of CPT codes that require prior authorization, eviCore clinical guidelines, and other provider resources on the eviCore Implementation Resources website.

### To view CPT Code lists:

- Access the 'Provider Section' of the Blue Cross website at providers.bluecrossmn.com
- Select "Medical Policy" under Tools and Resources, read and accept the Blue Cross Medical Policy Statement
- Under "Medical and Behavioral Health Policies" scroll down and click on the "eviCore healthcare Specialty Utilization Management Clinical Guidelines" link
- Select "Solution Resources" and then click on the appropriate solution (ex: Medical Oncology)
- Select "CPT Codes" to view the current CPT code list that require a prior authorization

Continued

### To view Clinical Guidelines:

- Access the 'Provider Section' of the Blue Cross website at providers.bluecrossmn.com
- Select "Medical Policy" under *Tools and Resources*, read and accept the Blue Cross Medical Policy Statement
- Under "Medical and Behavioral Health Policies" scroll down and click on the "eviCore healthcare Specialty Utilization Management Clinical Guidelines" link
- Click on the "Resources" dropdown in upper right corner
- Click "Clinical Guidelines"
- Select the appropriate solution: i.e. Medical Oncology
- Type "BCBS MN" (space is important) in 'Search by Health Plan'
- Click on the "Current", "Future", or "Archived" tab to view guidelines most appropriate to your inquiry

# To submit a Prior Authorization (PA) Request to eviCore

Providers submit eviCore PA requests via our free <u>Availity</u> provider portal. Instructions on how to utilize this portal are found on the Availity website.

Providers need to reference the eviCore clinical guideline criteria, submit prior authorization requests via Availity, and submit all applicable clinical documentation with the PA request. Failure to submit required information may result in review delays or denial of the request due to insufficient information.

### Note:

- An approved PA does not guarantee coverage under a subscriber's benefit plan. Subscriber benefit plans vary in coverage and some plans may not provide coverage for certain services discussed in the medical policies.
- Some of the Medical Oncology Drugs listed above may be approved by the Food and Drug Administration (FDA) for use treating non-oncology indications. To identify if a prior authorization for a drug for non-oncology use, please refer to the Prior Authorization Lists posted on the Blue Cross website. To access the Pre-Authorization Lists:
  - o Go to providers.bluecrossmn.com
  - Select "Medical Policy" under Tools and Resources, read and accept the Blue Cross Medical Policy Statement
  - o Review the lists under the "Utilization Management" section

## **Questions?**

If you have questions, please contact eviCore provider service at 844-224-0494.